Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) is currently the most aggressive subtype of breast cancer, characterized by high heterogeneity and strong invasiveness, and currently lacks effective therapies. PRMT5, a type II protein arginine methyltransferase, is upregulated in numerous cancers, including TNBC, and plays a critical role, marked it as an attractive therapeutic target. PROTAC (Proteolysis Targeting Chimeras) is an innovative drug development technology that utilizes the ubiquitin-proteasome system (UPS) to degrade target proteins, which is characterized by higher activity, enhanced safety, lower resistance, and reduced toxicity, offering significant value for clinical translation.

Methods

This study utilizes the PROTAC technology to develop potential degrader

SUBMITTER: Guo Y 

PROVIDER: S-EPMC11607928 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature